Home / Knowledge hub /
Navigating the transition to next-generation propellants for pMDIs | On-demand webinar
December 10, 2025
Regulators, health systems and patients expect meaningful progress on sustainability. For pressurized metered dose inhalers (pMDIs), this means planning the transition to low global warming potential (low-GWP) next-generation propellants (NGPs) now, not at the end of the decade.
In this webinar with Pharmaceutical Technology, Craig Somerville, Senior Vice President of Kindeva’s pMDI business unit, shares a practical view of what it takes to move existing products to NGPs while maintaining performance, supply continuity and patient need for MDIs.
Drawing on Kindeva’s pMDI pedigree built on inventing and industrializing the MDI, and its current investments in commercial-scale NGP capability, Craig outlines how a strategic drug delivery CDMO partner can help you move from feasibility to full-scale commercial supply with confidence.
Highlights include:
- The drivers accelerating the shift to NGPs
- What NGP-ready manufacturing and reformulation require
- Key considerations for HFA-152a and maintaining equivalent MDI performance
- How regulators are approaching the transition
- Where Kindeva adds value from feasibility through to commercial supply
Watch the webinar →
Access this content
Fields marked with a * are required.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
PharmaSource podcast with Tommy Schornak
Today’s pharmaceutical companies must manage tight timelines and high demand for products, as well as shifting regulatory requirements and an increasingly complex global supply chain. How can contract development and manufacturing organizations (CDMOs) rise to this challenge and provide the support they need? In this podcast with PharmaSource, Tommy Shornak, Senior Vice President, Sterile Injectables, […]
Learn More
The bridge to uncompromising fill finish precision
Sterile fill finish is a sequence of tightly connected control points, where performance at each stage directly influences quality, timelines and patient safety. Bridgeton is designed to deliver control at every step of the fill finish journey. Our 155,000 sq. ft. aseptic facility combines advanced automation, gloveless isolator technology and structured process design to reduce […]
Learn More
The bridge to the future of sterile injectables
Access a sterile fill finish solution designed to help your product progress from formulation through commercial scale with greater confidence and control. Having invested over $200M in our purpose-built, Annex 1-aligned facility in Bridgeton, MO, we bring together the infrastructure, expertise and control needed to accelerate your path to market. From early development through to […]
Learn More
Your bridge to commercial sterile manufacturing
Sterile fill finish has changed. Annex 1 compliance and data transparency are no longer future considerations; they are the baseline. At the same time, programs are expected to move faster, scale seamlessly and maintain absolute control from the first clinical batch through commercial supply. Siloed models cannot keep up with the pace and control required […]
Learn More
Manufacturing more sustainable tomorrows for pulmonary care
The shift to more sustainable inhalers is gaining pace. As pressure grows to reduce their environmental impact, low-Global Warming Potential (GWP) propellants are becoming an important part of the future of metered dose inhaler (MDI) development. In this infographic, we explore the trends shaping that transition, and share how Kindeva is helping partners prepare for […]
Learn More
Parenteral precision: Annex 1-ready sterile fill finish by design
Parenteral precision is a blog series exploring the controls, technologies and design decisions that shape modern parenteral manufacturing. Each article looks at one capability through a practical lens: what it is, how it works, who it supports and why it matters. This first blog focuses on Annex 1-ready sterile fill finish. As the European Union […]
Learn More
Beyond the bench: Aerosol analysis and the physics of MDI performance
Modern drug delivery is built on an architecture of precision and predictability to ensure patient safety. Behind every successful inhalation therapy lies a methodical application of analytical science that characterizes the behavior of complex aerosol systems. In this Beyond the bench blog, we examine how this analytical backbone supports the development of pressurized metered-dose inhalers […]
Learn More
Powering every breath you give: Our world-class Loughborough site
Pulmonary drug delivery is undergoing a period of rapid change. Developers must bring increasingly complex therapies to market while preparing inhalers for the transition to low-Global Warming Potential (GWP) propellant technologies. Success depends on having expertise across formulation, device integration and scalable manufacturing capabilities. Kindeva’s Loughborough, UK facility stands ready for this evolution. Our global […]
Learn More
Parenteral capabilities overview
Next-generation biologics and combination products require precision and close coordination between drug delivery technologies and manufacturing execution. Kindeva advances parenteral programs across development and commercial supply by bringing together device expertise, aseptic manufacturing and scalable operations. Why choose Kindeva for your parental program Large-scale sterile fill finish The Bridgeton site supports vial, cartridge and prefilled […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.